Current Pharmaceutical Biotechnology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Icariin Attenuates Human Renal Tubular Epithelial Cell Senescence by Targeting PAK2 via miR-23b-3p
CONCLUSION: miR-23b-3p and PAK2 form a signaling axis that regulates RTEC senescence upon urine exosome stimulation. Icariin can increase the resistance of RTECs against senescence via miR-23b-3p/PAK2. Our findings shed light on the mechanism of the clinical effects of icariin on renal diseases, which can be exploited to develop effective drugs targeting RTEC senescence in the future.PMID:38375837 | DOI:10.2174/0113892010276372231129105022 (Source: Current Pharmaceutical Biotechnology)
Source: Current Pharmaceutical Biotechnology - February 20, 2024 Category: Biotechnology Authors: Suqin Zhang Yanbin Li Qiuyue Wang Source Type: research

The Use of Lipid-Based Nanocarriers to Improve Ovarian Cancer Treatment: An Overview of Recent Developments
Curr Pharm Biotechnol. 2024 Feb 14. doi: 10.2174/0113892010279572240126052844. Online ahead of print.ABSTRACTOvarian cancer poses a formidable health challenge for women globally, necessitating innovative therapeutic approaches. This review provides a succinct summary of the current research status on lipid-based nanocarriers in the context of ovarian cancer treatment. Lipid-based nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), offer a promising solution for delivering anticancer drugs with enhanced therapeutic effectiveness and reduced adverse effects. Their v...
Source: Current Pharmaceutical Biotechnology - February 15, 2024 Category: Biotechnology Authors: Junaid Tantray Akhilesh Patel Bhupendra G Prajapati Sourabh Kosey Sankha Bhattacharya Source Type: research

The Role of NAD+ in Myocardial Ischemia-induced Heart Failure in Sprague-Dawley Rats and Beagles
CONCLUSION: The ratios of heart weight indexes, fibrotic areas, and MI rates in the CZ696 and medium and high NAD+ dose groups were lower than those in the HF group. Medium and high-dose NAD+ showed superior positive effects on myocardial hypertrophy, cardiac function, and myocardial fibrosis and reduced the MI rate.PMID:38357951 | DOI:10.2174/0113892010275059240103054554 (Source: Current Pharmaceutical Biotechnology)
Source: Current Pharmaceutical Biotechnology - February 15, 2024 Category: Biotechnology Authors: Zuowei Pei Chenguang Yang Ying Guo Min Dong Fang Wang Source Type: research

Unconventional Remedies for Squamous Cell Carcinoma: A Journey into Alternative Treatments
Curr Pharm Biotechnol. 2024 Feb 12. doi: 10.2174/0113892010286715240119061108. Online ahead of print.ABSTRACTSquamous cell carcinoma (SCC) is the second most common form of skin cancer and is typically found on sun-exposed skin. Risk factors include ultraviolet radiation exposure, older age, fairer complexion, smoking, and immunosuppression. SCC is a slow-growing tumor with the possibility of metastasis if not treated. The clinical presentation can range from a dry, scaly erythematous patch or plaque to a firm hyperkeratotic papule, plaque, or nodule, depending on the histological type via biopsy. The first-line therapies ...
Source: Current Pharmaceutical Biotechnology - February 13, 2024 Category: Biotechnology Authors: Elen Deng Amor Kachemoune Source Type: research

Traditional Chinese Medicine-based Treatment in Cardiovascular Disease: Potential Mechanisms of Action
Curr Pharm Biotechnol. 2024 Feb 12. doi: 10.2174/0113892010279151240116103917. Online ahead of print.ABSTRACTCardiovascular Disease (CVD) is the leading cause of morbidity and death worldwide and has become a global public health problem. Traditional Chinese medicine (TCM) has been used in China to treat CVD and achieved promising results. Therefore, TCM has aroused significant interest among pharmacologists and medical practitioners. Previous research showed that TCM can regulate the occurrence and development of atherosclerosis (AS), ischemic heart disease, heart failure, myocardial injury, and myocardial fibrosis by inh...
Source: Current Pharmaceutical Biotechnology - February 13, 2024 Category: Biotechnology Authors: Lanlan Li Yutong Ran Jiao Wen Yirui Lu Shunmei Liu Hong Li Min Cheng Source Type: research

Naringenin Nanoformulations for Neurodegenerative Diseases
Curr Pharm Biotechnol. 2024 Feb 12. doi: 10.2174/0113892010281459240118091137. Online ahead of print.ABSTRACTGlioblastoma (GBM) is a grade-IV astrocytoma, which is the most common and aggressive type of brain tumor, spreads rapidly and has a life-threatening catastrophic effect. GBM mostly occurs in adults with an average survival time of 15 to 18 months, and the overall mortality rate is 5%. Significant invasion and drug resistance activity cause the poor diagnosis of GBM. Naringenin (NRG) is a plant secondary metabolite byproduct of the flavanone subgroup. NRG can cross the blood-brain barrier and deliver drugs into the ...
Source: Current Pharmaceutical Biotechnology - February 13, 2024 Category: Biotechnology Authors: Liza Sahoo Nigam Sekhar Tripathy Fahima Dilnawaz Source Type: research

RNA-Based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment
Curr Pharm Biotechnol. 2024 Feb 12. doi: 10.2174/0113892010291042240130171709. Online ahead of print.ABSTRACTIt is becoming more and harder in today's climate to disregard the impact of cancer on social health. Even though a significant amount of money is spent annually on cancer research, it still ranks as the second leading cause of death worldwide. Additionally, only about half of the patients suffering from complex forms of cancer survive a year after receiving traditional cancer therapies. A method for silencing genes is called RNA interference (RNAi). Such a method is very effective in focusing on genes linked to can...
Source: Current Pharmaceutical Biotechnology - February 13, 2024 Category: Biotechnology Authors: Anjana Goel Amisha Rastogi Mansi Jain Kinjal Niveriya Source Type: research